InFocus: Genomics & Rare Diseases in the Middle East

2026

For decades, the Middle East carried some of the world’s highest rates of inherited genetic disease, and almost none of the research data needed to treat it. That equation has flipped, fast. Saudi Arabia, the UAE, and Qatar have spent the past decade building sovereign, population-scale genome programs, backed by real capital and paired with regulatory systems fast enough to act on what they find.

The numbers are striking: genetic carrier rates that hit 25 percent in some populations, versus roughly two percent in typical Western screening. A single founder mutation behind nearly all Qatari homocystinuria cases, a level of genetic homogeneity researchers can rarely find elsewhere. And global biotechs taking notice: Vertex delivered its CRISPR-based gene therapy for beta-thalassaemia outside a clinical trial for the first time anywhere in the world, in Saudi Arabia. Novartis and Biogen have relocated leadership functions into the region rather than manage them remotely, chasing research questions that can be asked and answered faster here than almost anywhere else.

This report tracks how that happened, from world-first therapy approvals and newborn screening programs already running at national scale, to the next wave of multi-omics research and regenerative medicine now taking shape. 20years ago, a rare disease diagnosis in this region often meant a long wait, a trip abroad, or no answer at all. Today, that same genetic density is being reframed as one of the most valuable scientific resources in global medicine, and this report explains why.

Articles

Rare Disease Market Access in the Gulf: Keeping Pace with the FDA

Once regarded as a strategic afterthought by international biopharma, the Middle East has undergone a profound transformation in recent years, emerging as an early adopter of next-generation therapies for rare diseases. Regional regulatory authorities are accelerating approval timelines, reflecting an aggressive institutional ambition to secure speedy access to cutting-edge medical science. “In some cases,…

National Genome Programmes in the Gulf: Mapping the Middle East’s Genome

A quarter-century after the Human Genome Project revolutionized biology, genomic sequencing has matured from an ambitious scientific frontier into an indispensable clinical reality. Today, molecular insights routinely guide everything from targeted oncology to rare disease diagnostics. Yet, this genomic revolution harbours a profound systemic bias: nearly 90 percent of all sequenced cohorts are restricted to…

Rare Disease Clinical Trials in the Gulf: Inside an Investment Boom

Long regarded as a clinical trials backwater, the Middle East has experienced a tremendous surge in clinical research over the past five years. This boom is fuelled by a global demand for representational equity and an urgent need to correct a stark imbalance, as Middle Eastern populations currently account for just 1.24 percent of global…

Cell and Gene Therapy: The Rise of Advanced Therapeutics in the GCC

After years of foundational investment in genomics, population screening, and rare disease diagnostics, Gulf nations are entering a transformative era: the delivery of advanced therapeutics. The cell and gene therapy (CGT) landscape within the GCC has fundamentally shifted from importing foreign cures to establishing localized, highly sophisticated manufacturing and clinical ecosystems. Propelled by ambitious national…

How the Middle East Became a Global Force in Thalassaemia Research

The Middle East contains one of the world’s strongest concentrations of expertise in the rare blood disorder thalassaemia. The story starts with the high prevalence of this disease in the region – thalassaemia affects roughly one in 100,000 people globally but reaches up to ten percent of the population in certain Middle Eastern countries –…